SIGNAL // LOADING
Loading page
Recovery
Research peptideBPC-157 Peptide
Gastric-derived pentadecapeptide with preclinical signal on tendon, ligament, and gut repair. Run as a supervised, time-limited cycle, not a lifelong protocol.
Subscribe & Save
Easy to cancel anytime
$179/mo
One Time Purchase
Available after provider review
$179
Nothing ships until intake clears a licensed provider. If the pathway isn't right, we say so.
Key Benefits
- Compelling preclinical data on tendon and ligament repair
- Short, cycled protocols - no open-ended dosing
- Eligibility paired with imaging or clinical rehab plan where relevant
- Labs bracket every cycle, same as NAD+
Clinical Rationale
BPC-157 is a synthetic peptide derived from a gastric protein with documented preclinical activity on angiogenesis, NO-pathway signaling, and growth-factor expression in tendon and mucosal tissue. Human clinical evidence is limited to small series. ALUKARD offers it as a supervised 4-6 week cycle for specific recovery indications, not as a standing order.
DirectionsAdminister as prescribed by your provider. Dosing, route, and cycle length are individualized based on indication and evidence tier.
Safety Notes
Prescription products require clinical eligibility and provider approval.
Medication availability varies by state and clinical criteria.
Research peptide - human efficacy data is limited.
Fit check
Who this is for - and who it isn't
Who this is for
- Members with a diagnosed tendinopathy or connective-tissue injury with an active rehab plan
- Adults with functional gut-lining concerns where conventional care has been exhausted
- Anyone who wants a time-boxed, data-honest peptide cycle
Who this isn't for
- Active or recent cancer diagnosis - angiogenic effects are theoretical risk
- Pregnancy or breastfeeding
- Anyone expecting lifelong daily dosing or cosmetic claims
Using it well
How to combine and what to watch for
How to combine
- Pair with a real rehab protocol - peptides don't replace loading
- Sleep floor of seven hours does more for connective tissue than any peptide
- Retest inflammatory markers and CBC at the close of each cycle
Safety considerations
- Injection-site redness and mild fatigue are the most common reports
- Stop and escalate for new lumps, persistent rash, or cardiovascular symptoms
- State-level compounding rules determine availability
Quality Standards
Third-party tested where applicable. Every regulated Rx clears licensed provider review under state rules - no exceptions.
What membership unlocks
- + Provider-managed cycles
- + Labs bracket each cycle
- + Coaching-linked rehab support
Run the labs first
Most protocols perform better when the baseline is measured before you start. Add ApoB, HbA1c, fasting insulin, and the hormones that matter for your goal.
See lab packagesGenerative engine summary
BPC-157 Peptide in three clean lines.
- BPC-157 Peptide sits inside ALUKARD's recovery path and is built to pair with labs or provider-reviewed care when the goal calls for it.
- Regulated. Every script clears intake, eligibility, and licensed-provider review - no same-day approvals.
- BPC-157 is a synthetic peptide derived from a gastric protein with documented preclinical activity on angiogenesis, NO-pathway signaling, and growth-factor expression in tendon and mucosal tissue. Human clinical evidence is limited to small series. ALUKARD offers it as a supervised 4-6 week cycle for specific recovery indications, not as a standing order.
Where we ship
BPC-157 Peptide is gated by state licensure and pharmacy access. Confirm eligibility in your state before you book the assessment.
Related Glossary
The terms BPC-157 Peptide runs into.
Peptide
A short chain of amino acids (<50) that signals specific receptors - not all are drugs, not all are safe.
BPC-157
Research peptide with strong preclinical data on connective-tissue repair. Limited human evidence.
Oral BPC-157
Oral BPC-157 is a medication or peptide considered in targeted protocols with clinician oversight.
Questions
Before you start, the questions we actually get.
Is this FDA-approved?
No. BPC-157 is a research peptide with strong preclinical data and limited human trials. We offer it as a supervised, time-limited option with clear eligibility and labs - not as a consumer supplement.
How long is a cycle?
Typically 4-6 weeks. Longer windows rarely improve outcomes and start to outrun the available safety data. A second cycle is possible after a wash-out if indicated.
BPC-157 vs TB-500?
Different mechanisms, different evidence base. BPC-157 has more published tendon and GI signal; TB-500 sits earlier on the evidence curve. We choose based on the specific case, not a generic stack.
Who gets declined?
Active oncology cases, pregnancy, members expecting lifelong dosing, or anyone without a concrete indication beyond general biohacking curiosity.